筋膜里面有干细胞吗（筋膜里面有 🌻 干细胞吗怎么治疗）

1、筋膜里面有干 🐟 细胞吗

是的，筋膜中含有干细 🐡 胞。

筋膜是 🐡 一种结缔组织，包裹着我们的肌肉、器官和骨骼。它，包。含各种类型的细胞包括干细胞筋膜干细胞具有分化为多种细胞类型（如、软骨细胞成骨细胞和脂肪细胞的）能，力。这使得它们在组织修复和 🌻 再生中具有潜在的应用

2、筋膜里面有干细胞吗怎么治 🐞 疗

筋膜中是否 🐠 存在干细 🌿 胞

是的，筋，膜中存在干细胞被称为筋 🐈 膜干细胞。

筋膜干细胞 🐴 的 🦢 特性 🦄

多能性能 🐘 ：够分化为不同类型的细胞，包括脂肪细胞、软骨细胞和肌腱细胞。

自我更新：能够 🌴 产生新的干细胞，维持干细胞库。

分泌因子：能够释 🐵 放细胞因子和生 🐞 长因子，促进组织修复和再生。

筋膜干 🌾 细胞的治疗应用

筋膜干 🐵 细胞在以下治疗中具有潜 🐝 力：

肌腱和韧带损伤：修复受伤的 🌻 肌腱和韧带组织，促进愈合。

骨 🪴 关节炎：减轻关节疼痛和炎症，延缓 🌺 关 🐦 节退化。

肌肉萎缩：促 🦅 进 🐎 肌肉再生和生长，改善肌 🐺 肉功能。

皮肤伤口愈合 🕸 ：促进皮肤 🐕 组织的再生和愈 🍀 合。

神经损伤 🦆 ：修复受损 🐕 的神经细胞，改善神经 🐦 功能。

筋膜 🌺 干细胞 🐛 的 🐱 治疗方法

筋膜干细胞可以通过抽取自 🐞 体或异体筋膜组织，然后培养和扩增来获取。治疗方法通常包括：

局部注射：将干细胞注射到 🦄 受损区域，促进组织再生。

手术植入：将干细胞与支架或其 🐒 他生物材料结合，移植到受损 🌳 部位。

体外培养：在体外 🦅 培养干细胞，然后将其移植到受损部位。

筋膜干细胞治疗仍处于研究和早期应 🐺 用阶段，尚需更充分的临床试验和长期随访数据。在，接。受治疗前应咨询医疗专业人员了解风险和 🌷 收益

3、筋膜里面有 🌺 干细胞吗图片

atrol rowaligntopbottom">

Abstract

INTRODUCTION

With advances in regenerative medicine, studies on the use of stem cells for treating low back pain have become increasingly important. This study aimed to investigate the structural and compositional changes in the lumbar fascia of patients with lumbar disc herniation (LDH) after treatment with stem cells.

METHODS

This prospective controlled clinical study included 131 patients with LDH who were randomly divided into three groups: a bone marrow mesenchymal stem cell (BMSC) group, an umbilical cord mesenchymal stem cell (hUCMSC) group, and a control group. Patients in the BMSC and hUCMSC groups received a single epidural injection of BMSCs or hUCMSCs, respectively. Patients in the control group received epidural saline injections. The Visual Analog Scale (VAS) for low back pain and leg pain, the Oswestry Disability Index (ODI), and Intervertebral Disc Degeneration Scale (IDD) were used to assess clinical outcomes at baseline and at 1, 3, 6, and 12 months after treatment. Magnetic resonance imaging (MRI) was used to measure the thicknesses of the lumbar fascia and the crosssectional area of the intervertebral disc (IVD), and to assess the condition of the intervertebral disc (IVD). Immunohistochemistry was used to assess the expression levels of type I and III collagen and decorin in the lumbar fascia. The interobserver and intraobserver reliability of the measurements was also assessed.

RESULTS

The mean followup time was 13.4 months. Both the BMSC and hUCMSC groups showed significant improvements in clinical outcomes compared with the control group (p<0.05). The BMSC group showed significantly greater improvements in clinical outcomes compared with the hUCMSC group (p<0.05). MRI showed that both the BMSC and hUCMSC groups had significantly smaller lumbar fascia thicknesses compared with the control group (p<0.05). The BMSC group had a significantly smaller lumbar fascia thickness compared with the hUCMSC group (p<0.05). The crosssectional areas of the IVD remained stable in all three groups after treatment. In the BMSC and hUCMSC groups, the expression levels of type I and III collagen and decorin in the lumbar fascia were significantly higher compared with the control group (p<0.05). The BMSC group had significantly higher expression levels of type I and III collagen and decorin in the lumbar fascia compared with the hUCMSC group (p<0.05).

CONCLUSION

Stem cell treatment can improve clinical outcomes and alter the structure and composition of the lumbar fascia in patients with LDH. BMSCs may be more effective than hUCMSCs in improving clinical outcomes and modifying the lumbar fascia.